- Home
- / XPhyto Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
XPhyto Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.5
2023-01-13
Revenue
$27 K
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CAD | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|
| Revenue | 208.0K | 345.0K | 286.0K | 297.0K | 372.0K | 27.0K |
| Cost of goods sold | 87.0K | 102.0K | ||||
| Gross profit | 208.0K | 345.0K | 199.0K | 195.0K | 372.0K | 27.0K |
| Gross profit margin, % | 100.0% | 69.6% | 65.7% | 100.0% | 100.0% | |
| Operating expense total | 4.4M | 8.6M | 10.3M | 3.3M | 2.7M | 4.5M |
| Depreciation and amortization | 1.4M | 2.9M | 4.3M | 6.1M | 253.0K | 92.0K |
| EBITDA | (4.1M) | (8.3M) | (10.1M) | (3.1M) | (2.3M) | (4.5M) |
| EBITDA margin, % | -1993.3% | -3525.9% | -1042.8% | -627.4% | -16577.8% | |
| EBIT | (5.5M) | (11.1M) | (14.5M) | (9.1M) | (2.9M) | (4.5M) |
| EBIT margin, % | -2661.1% | -5074.5% | -3063.6% | -767.5% | -16796.3% | |
| Interest expense | 105.0K | 297.0K | 732.0K | 1.1M | 1.0M | 985.0K |
| Pre tax profit | (7.7M) | (17.2M) | (20.7M) | (12.9M) | (7.7M) | (5.4M) |
| Income tax expense | (45.0K) | (358.0K) | (110.0K) | (493.0K) | (90.0K) | |
| Net Income | (7.7M) | (16.9M) | (20.6M) | (12.4M) | (7.7M) | (5.3M) |